Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Beluga Health vs JRNYS

Beluga Health
Graded #431

Lower grade

vs+6.700000000000003
JRNYS
Graded #271

Higher grade

The verdict

JRNYS takes it — 62.5/100 to 55.8/100.

JRNYS grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. JRNYS is a telehealth weight-loss membership built around branded GLP-1 medications, and the membership itself buys no medication.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationJRNYS +18
40
58
Clinical oversightJRNYS +8
76
84
Labs & monitoringJRNYS +9
62
71
FulfillmentJRNYS +1
64
65
Contract termsEven
55
55
Beluga Health · left barJRNYS · right bar

The numbers

MetricBeluga HealthJRNYS
WeighScore55.8/10062.5/100
GradeCC
Scorecard rank#431#271
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Beluga Health

Graded #431 · C

Strengths

  • Supports GLP-1 care with compounded semaglutide and tirzepatide
  • Board-certified providers and a 50-state medical infrastructure
  • LegitScript certified with SOC 2 and ISO 27001 security
  • Pharmacies follow FDA/USP standards with third-party batch testing
  • Powers many DTC brands as a turnkey telehealth backbone

Where it loses points

  • White-label B2B group, not a direct consumer-facing service
  • Offers compounded, not FDA-approved branded, GLP-1s
  • No public consumer pricing for the GLP-1 offering
  • Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
  • Care quality varies by the consumer brand using the platform
JRNYS

Graded #271 · C

Strengths

  • Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
  • The membership band is published before intake and is banded openly by level of coach support
  • Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
  • Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
  • Members with commercial insurance may pay around $25 a month for the medication after any deductible

Where it loses points

  • The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
  • No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
  • The best case depends on commercial insurance coverage; without it the medication cost is unknown
  • No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
  • The states it can prescribe in are not published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard